By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works Collective
  • Health
    • Mental Health
    Health
    Healthcare organizations are operating on slimmer profit margins than ever. One report in August showed that they are even lower than the beginning of the…
    Show More
    Top News
    healthcare cybersecurity
    4 Helpful Tips on How to Protect Your Medical Practice Against Cyber Attacks
    October 24, 2021
    Health Check Diagnosis Medical Condition Analysis Concept
    6 Health Woes With Online Remedies
    January 19, 2022
    Eight Things Men Should Know About the Male Menopause
    Eight Things Men Should Know About the Male Menopause
    April 24, 2022
    Latest News
    The 6 Most Common Injuries Resulting from Motorcycle Accidents
    January 30, 2023
    6 Essential Strategies for Improving Your Medical Practice
    January 25, 2023
    Staying Positive While Living with Mesothelioma
    January 24, 2023
    The Many Health Benefits of Being Outdoors
    January 17, 2023
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
    Policy and Law
    Get the latest updates about Insurance policies and Laws in the Healthcare industry for different geographical locations.
    Show More
    Top News
    Ultraprocessed Foods Lead to Chronic Illnesses
    April 18, 2011
    Cancer/Cell Phone Connection Challenged
    June 7, 2011
    States Ranked by Percent Obese Highlights Pervasive Negative Trend
    July 11, 2011
    Latest News
    Why Is a Referenced Based Pricing Tool Necessary?
    February 3, 2023
    Simplifying the Genetic Testing Process: How At-Home Kits are Changing the Game
    January 25, 2023
    9 Hospitals That Have Introduced Green Initiatives
    February 1, 2023
    Why a Health Retreat Can Be the Best Medicine
    January 12, 2023
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Is pharma industry too meek on pricing?
Share
Sign In
Notification Show More
Latest News
Why Is a Referenced Based Pricing Tool Necessary?
Health care
struggling with addiction
6 Signs Someone You Know Is Struggling With Addiction
Addiction Addiction Recovery
regrow teeth naturally
Advances in Stem Cell Research Can Help Regrow Teeth Naturally
Dental health
air pollution and cancer
The Proven Links Between Air Pollution and Cancer
News
investing in senior care
5 Reasons Why Investing in Senior Care Is a Wise Choice?
Senior Care
Aa
Health Works CollectiveHealth Works Collective
Aa
Search
Have an existing account? Sign In
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Business > Hospital Administration > Is pharma industry too meek on pricing?
Hospital AdministrationMedical EthicsTechnologyWellness

Is pharma industry too meek on pricing?

DavidEWilliams
Last updated: 2016/04/03 at 12:00 PM
DavidEWilliams
Share
6 Min Read
SHARE
ID-100146535

What were we thinking?

ID-100146535

What were we thinking?

More Read

green hospitals

9 Hospitals That Have Introduced Green Initiatives

New Year, New Healthy Changes for Your Diet
The Benefits of Using a Healthy Food Delivery Service
Don’t Let These 3 Mistakes Lower Your Immune System
Best Money-Saving Tips for Health Managers

The biopharmaceutical industry has been under attack for some time for the high and rising prices of its products. Pressure has increased recently with the arrival of costly medications for oncology, hepatitis, high cholesterol and more. Expect even further pressure as more specialty drugs are introduced, and then really significant pushback once seriously costly innovations such as gene therapy come online.

I’ve noticed that the pool of people complaining about drug pricing is widening. Now, even doctors are picking up the megaphone. For example, the American College of Physicians (ACP) recently made the case for drug price controls in a position paper. Recommendations include requiring companies to disclose R&D and materials costs, allowing the use of Quality Adjusted Life Years (QALYs) in research funded by the Patient-Centered Outcomes Research Institute (PCORI), having Medicare negotiate prices, enabling reimportation of drugs from lower-priced markets, ensuring that restrictive formularies don’t price patients out of the market by requiring excessive cost sharing, etc.

For all its spending and glitz, the industry’s main lobbyist (PhRMA) hasn’t managed to stave off the attacks. In fact some of its past and current arguments are digging the industry into a deeper hole. Here’s what PhRMA said in response to a MedPage Today inquiry on the ACP position paper:

In an email to MedPage Today, a spokesperson for the Pharmaceutical Research and Manufacturers of America (PhRMA) called the recommendations “far-reaching,” and “driven by the false notion that spending on medicines is fueling overall healthcare cost growth.”

There are a couple of important things the industry is doing wrong:

PhRMA has placed huge emphasis on how expensive it is to develop a drug, and strongly implied that drug prices are based on the costs of R&D. The general public more or less accepted the old $1 billion per drug benchmark, but I’m not sure even the industry believes the $2.6 billion for a new drug figure PhRMA has been using since 2014. And –just like in other industries– manufacturers don’t set prices based on what they spent on R&D.

So while PhRMA may complain about requests for “transparency” on R&D spending –and I agree this information is worthless, not to mention time consuming and expensive to collect– the industry brought the issue on itself.

As the email to MedPage shows, PhRMA’s current argument is that drugs are not driving up total medical costs. In other words, money spent to pay for new drugs is saved elsewhere in the system, for example by reducing hospitalizations, doctor visits or surgeries.

This cost-saving/cost-neutral argument demonstrates to me that PhRMA has not learned its lesson from the failure of its R&D spending-based approach for sympathy. The R&D approach implies a willingness to live with “cost plus” pricing. And the cost-saving argument ignores the possibility that a drug is not just a cheaper alternative to existing approaches but actually a better one. For example, the value of a cure for Hepatitis C extends beyond the financial cost of a liver transplant.

Here are a few suggestions for PhRMA:

  • Embrace the concept of Quality Adjusted Life Years (QALY) to measure the value of an intervention. But don’t settle for the arbitrary $50,000 threshold that researchers often use to judge whether a therapy is worthwhile.
  • Push back against the ACP and other physician critics of pharma pricing by insisting that the QALY approach be used to measure not just pharma but the work that the rest of the healthcare system does. The QALY concept can be applied to procedures, devices and maybe to hospitalizations and office visits. A lot of what’s done in healthcare today can’t demonstrate any value on the QALY scale, so maybe those things should be eliminated or have their reimbursements cut in order to increase affordability or make room for better interventions.
  • Prepare the public for more costly innovations like gene therapy, which have the potential to be transformative for sick individuals but are very expensive. If I or someone else in my family is sick, I want the system to find a way to afford the innovation even if it doesn’t save costs anywhere else.

This is a tricky topic and I’ve just scratched the surface here. But bottom line PhRMA should at least prepare us for the possibility that its members will add to total costs, and that we should be ok with that outcome if the results are good enough.

Image courtesy of Stuart Miles at FreeDigitalPhotos.net

—-

By healthcare business consultant David E. Williams, president of Health Business Group.

 

TAGGED: drug pricing, pharmaceuticals

Sign Up For Daily Newsletter

Be keep up! Get the latest breaking news delivered straight to your inbox.
By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.
DavidEWilliams April 3, 2016
Share this Article
Facebook Twitter Copy Link Print
Share
Previous Article Two Truths and a Lie about Physicians and Social Media
Next Article Mistakes Practices Make On Their Website and Social Media

Stay Connected

1.5k Followers Like
4.5k Followers Follow
2.8k Followers Pin
136k Subscribers Subscribe

Latest News

Why Is a Referenced Based Pricing Tool Necessary?
Health care February 3, 2023
struggling with addiction
6 Signs Someone You Know Is Struggling With Addiction
Addiction Addiction Recovery February 2, 2023
regrow teeth naturally
Advances in Stem Cell Research Can Help Regrow Teeth Naturally
Dental health February 1, 2023
air pollution and cancer
The Proven Links Between Air Pollution and Cancer
News February 1, 2023

You Might also Like

investing in senior care
Senior Care

5 Reasons Why Investing in Senior Care Is a Wise Choice?

January 30, 2023
Personal Injury Healing Tips and Strategies
Health

Personal Injury Healing Tips and Strategies

January 28, 2023
lifestyleWellness

Small Lifestyle Changes That Can Have A Big Impact On Your Well-Being

January 26, 2023
The Future Of Medicine: How Immunotherapy Is Saving Lives
Technology

The Future Of Medicine: How Immunotherapy Is Saving Lives

January 26, 2023
//

We influence million of users and is the most authentic source of information on healthcare business and technology news.

Quick Links

  • About
  • Contact
  • Privacy
Subscribe

Subscribe to our newsletter to get our newest articles instantly!

Follow US

© 2008-2023 HealthWorks Collective. All Rights Reserved.

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?